



Title	Cross-talk between bone morphogenic proteins and estrogen receptor signaling.
Author(s)	Yamamoto, Tetsuya; Saatcioglu, Fahri; Matsuda, Tadashi
Citation	Endocrinology, 143(7), 2635-2642 https://doi.org/10.1210/endo.143.7.8877
Issue Date	2002-07
Doc URL	http://hdl.handle.net/2115/28136
Type	article (author version)
File Information	EN143-7.pdf



[Instructions for use](#)

**Title: Cross-talk between Bone Morphogenic Proteins and
Estrogen Receptor Signaling**

Abbreviated title: Cross-talk between BMPs and ER

Tetsuya Yamamoto*§, Fahri Saatcioglu¶, and Tadashi Matsuda*§

*Department of Immunology,

Graduate School of Pharmaceutical Sciences, Hokkaido University

Kita-ku Kita 12 Nishi 6, Sapporo 060-0812, Japan

¶Department of Biology, University of Oslo

Boks 1066 Blindern, 0316 Oslo, Norway

Key words: BMP; Smad; 17 β -estradiol; ER; cross-talk; transcription

§These authors contributed equally to this work. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture in Japan, the Sagawa Foundation for Promotion of Cancer Research, and Norwegian Research Council.

Address correspondence to: Dr. Tadashi Matsuda, Department of Immunology,
Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-ku Kita 12 Nishi 6,
Sapporo 060-0812, Japan TEL: 81-11-706-3243, FAX: 81-11-706-4990, E-mail:
tmatsuda@pharm.hokudai.ac.jp

Abstract

Bone morphogenic proteins (BMPs) play central roles in differentiation, development, and physiologic tissue remodeling. Estrogens have key roles in variety of biological events, such as the development and maintenance of numerous target tissues. Previous studies demonstrated that estrogens suppress BMP functions by repressing BMP gene expression. Here we present a novel mechanism for the inhibitory effect of estrogens on BMP function. BMP-2-induced activation of Sma and MAD-related protein (Smad) activity and BMP-2-mediated gene expression were suppressed by 17β -estradiol (E2) in breast cancer cells and mesangial cells. E2-mediated inhibition of Smad activation was reversed by Tamoxifen, an ER antagonist. We provide evidence that the inhibitory action of ER on Smad activity was due to direct physical interactions between Smads and ER which represents a novel mechanism for the cross-talk between BMP and ER signaling pathways.

Introduction

Bone morphogenetic proteins (BMPs) are members of the transforming growth factor β (TGF- β) superfamily that have been implicated in tissue growth and remodeling (1, 2, 3). BMPs were initially identified by the ability of bone extracts to induce bone formation at extraskeletal sites (2). BMPs bind to two types of transmembrane receptors, denoted type I and type II BMPRs, which have serine/threonine kinase activity (3). Upon ligand binding, type II receptors phosphorylate the type I receptors. The activated type I receptors then phosphorylate downstream Smads, Smad1, Smad5 or Smad8, which are transcription factors that regulate gene expression in response to BMPs (4, 5, 6).

Estrogen receptor (ER) is a ligand-activated transcription factor that is a member of the nuclear receptor superfamily (7). Two types of ERs have been identified, ER α and ER β , that appear to have overlapping, but distinct roles in mediating estrogen action (8, 9, 10). Estrogens play important roles in the differentiation and development of various organs, maintenance of proper cellular function in a wide variety of tissues, and are also risk factors for breast and endometrial cancer (11). ERs interact with estrogen response elements (EREs) in the target gene promoters and directly regulate their transcription (7). In addition, ERs interact with other signaling pathways for which DNA binding may not be necessary (12).

Bone morphogenetic protein-2 (BMP-2) has been shown to regulate chondrocyte differentiation and extracellular matrix composition. BMP-2, like TGF- β , up-regulated α 1(I)-collagen (COL1A1) mRNA expression in osteoblastic cells (13, 14). Furthermore, BMP-2-mediated transcription of α 1(I)-collagen (COL2A1) was blocked by expression of a dominant-negative Smad1 expression vector (15). In previous studies, estrogens have been shown to inhibit BMP functions in primary oviduct cells and osteoblasts by repressing BMP

production (16, 17). Estrogen administration has also been shown to reduce collagen deposition in the aorta of hypertensive and hypercholesterolemic animals and reduces collagen synthesis by vascular smooth muscle cells in vitro (18).

In this study, we demonstrate a novel molecular mechanism for the inhibitory actions of estrogens on BMP-2 function: there are direct physical and functional interactions between Smad and ER. These findings provide insights into the cross-regulation between the estrogen and BMP-2 signaling pathways that may have implications in reproductive physiology and the process of chondrogenesis.

Materials and Methods

Reagents and antibodies

Human recombinant BMP-2 was purchased from Strathmann Biotech GmbH (Germany). 17 β -estradiol (E2) and Tamoxifen were purchased from Wako Chemicals (Osaka, Japan). Expression vectors, FLAG-tagged Smad1, Smad5, BMPR-IA(QD) and 12xGCCG-LUC were kindly provided by Dr. M. Kawabata and Dr. K. Miyazono (The Cancer Institute of JFCR, Tokyo, Japan) (19, 20). Human ER α (HEG0), ER α L536P (HEG0L536P) (21), human ER β (22), and human α 2(I)-collagen (COL1A2) (23) and were kindly provided by Dr. P. Chambon (Institut de Chimie Biologique, Strasbourg, France), Dr. J. H. White (McGill Univ., Montreal, Canada), Dr. J. A. Gustaffson (Karolinska Institute, Stockholm), and Dr. H. Ihn (Tokyo Univ., Tokyo, Japan), respectively. ER α mutants were generated by PCR methods and sequenced (primer sequences are available upon request). Anti-HA, anti-Myc,

anti-ER α antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Anti-FLAG M2 antibody was purchased from Upstate Biotechnology (Lake Placid, NY).

Cell culture, transfections, and luciferase assays

Human embryonic kidney carcinoma cell line, 293T, was maintained in DMEM containing 10% FCS and transfected in DMEM containing 1% FCS by the standard calcium precipitation protocol. Human renal mesangial cells were obtained from Clonetics (East Rutherford, New Jersey) and cultured in MsGM (Clonetics) containing 5% FCS according to the manufacturer's instructions. Before stimulation, cells were cultured for 12 h in MsGM containing 1% FCS followed by treatment with BMP-2 and/or E2. Human breast cancer cell line MCF-7 was a kind gift from Cell Resource Center for Biomedical Research (Tohoku Univ., Sendai, Japan) maintained in DMEM containing 10% FCS (24). Before stimulation, the cells were cultured for 24 h in DMEM containing 1% FCS followed by treatment with BMP-2 and/or E2 (24, 25). MCF-7 cells ($2-2.5 \times 10^5$ in a 6-cm dish) were transfected by using LipofectAMINE PLUS (Life Technologies, Carlsbad, CA) following manufacturer's instructions. Luciferase assay was performed as described (26). The cells were harvested 48 h after transfection and lysed in 100 μ l of PicaGene Reporter Lysis Buffer (Toyo Ink, Tokyo, Japan) and assayed for luciferase and β -galactosidase activities according to the manufacturer's instructions. Luciferase activities were normalized to the β -galactosidase activities. Three or more independent experiments were carried out for each panel presented.

Immunoprecipitation and Western analysis

The immunoprecipitation and Western blotting were performed as described previously (26). Cells were harvested and lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, containing 0.5% NP-40, 1 μ M sodium orthovanadate, 1 μ M phenylmethylsulfonyl fluoride and 10 μ g/ml each of aprotinin, pepstatin and leupeptin). The immunoprecipitates from cell lysates were resolved on 5-20% SDS-PAGE and transferred to Immobilon filters (Millipore, Bedford, MA) which were then probed with each antibody. Immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).

Northern blot analysis

Human renal mesangial cells were maintained as described above. After 12 h of incubation in 1% FCS, cells were treated with BMP-2 (50 ng/ml) and/or E2 (10^{-8} M) for 24 h. Total RNA was prepared by using Iso-Gen (Nippon Gene, Tokyo, Japan) and used in Northern analysis according to established procedures. A nylon membrane (Hybond N⁺, Amersham Pharmacia Biotech) and radiolabelled cDNA probes were used, where indicated.

Results

Estrogens inhibit BMP-2-induced Smad activation

To examine whether estrogens have any effects on BMP-2-induced transcriptional activation of cellular genes, we carried out Northern analysis on RNA samples prepared from human renal mesangial cells which were induced by BMP-2 and/or E2. As a cellular target for BMP-2, we analyzed the expression of α 2(I)-collagen (COL1A2) that codes for a major

structural component of the extracellular matrix (27) and is upregulated by BMP-2 treatment (13, 14). As shown in Fig. 1A, BMP-2 treatment induced COL1A2 expression in human renal mesangial cells by 10-fold and this activation was decreased by 60% in the presence of E2, whereas E2 alone slightly increased basal levels of COL1A2 expression. These data show that E2 inhibits BMP-2-induced gene expression in human renal mesangial cells.

To further examine the molecular basis of the cross-talk between BMP-2 and estrogen signaling pathways, we utilized a BMP-2-responsive, ER-positive breast cancer cell line, MCF-7 (24, 25), and the transient transfection assay. The BMP-2-mediated transcriptional responses were measured by using 12xGCCG-LUC, which is a reporter construct that directly detects Smad phosphorylation, and therefore activation, by BMPRs (20). MCF-7 cells were transfected with 12xGCCG-LUC and treated with BMP-2 and/or E2 and LUC activities were determined. As shown in Fig. 1B, BMP-2 stimulated 12xGCCG-LUC activity approximately 4-fold, whereas E2 alone did not have an effect. When cells were treated with both BMP-2 and E2, 12xGCCG-LUC expression was decreased by 50% compared with the activation by BMP-2 alone.

Reconstitution of the cross-talk between BMP and ER signaling pathways in 293T cells.

To further delineate the mechanisms of cross-talk between BMP and ER signaling pathways, we carried out transient transfection experiments in 293T cells using the respective receptors and the downstream activators for the BMP signaling, Smad1 and Smad5. In addition, in some of these experiments, a constitutively active form of BMP type IA receptor, BMPR-IA(QD), was used (19).

When 293T cells were transfected with 12xGCCG-LUC together with an expression vector for BMPR-IA(QD), LUC expression increased by 3-4-fold (Fig. 2A). Additional

expression of Smad5 augmented 12xGCCG-LUC expression by 20-fold (Fig. 2A). We then examined the effect of E2 on BMP signaling in this model system. 293T cells were transfected with an expression vector for ER α , BMPR-IA(QD), Smad5 and 12xGCCG-LUC, and were either left untreated or treated with E2. As shown in Fig. 2A, E2 suppressed BMPR-IA(QD)/Smad5-induced 12xGCCG-LUC expression by approximately 50% in a dose-dependent manner. This inhibition was largely reversed in the presence of the anti-estrogen Tamoxifen (Fig. 2A). These results indicate that the inhibitory effects of E2 on BMPR-IA(QD)/Smad5-induced transcriptional activity are mediated by ER α and can be reconstituted in 293T cells similar to those observed in MCF-7 cells.

We then assessed the reverse situation for the possible effect of BMP signaling on ER α activity using the reporter gene Vit-LUC in which two copies of an estrogen response element (ERE) drive expression of the LUC gene. In the presence of ER α , E2 treatment resulted in a 50-fold increase in Vit-LUC activity (Fig. 2A). Surprisingly, this activation was augmented by BMPR-IA(QD)/Smad5 expression in a dose-dependent manner, up to approximately 3-fold more than by E2 alone, although BMPR-IA(QD)/Smad5 alone did not affect reporter activity (data not shown). These results suggest that in contrast with the inhibitory effects of ER α on BMP signaling, activation of the BMP pathway has stimulatory roles for ER α signaling in 293T cells.

We next examined if the other major ER isoform, ER β (8, 9), has similar inhibitory effects on TGF- β signaling in an analogous experiment. As shown in Fig. 2B, BMPR-IA(QD)/Smad5-induced 12xGCCG-LUC activity was inhibited by ER β in the presence of E2 similar to that observed with ER α , and this inhibitory effect was reversed by Tamoxifen. ER β -induced Vit-LUC activation was augmented by BMPR-IA(QD) and

Smad5, similar to that observed for ER α . These data suggest that both ER isotypes may be involved in the cross-talk of ER signaling with the BMP pathway.

To examine the interactions between the BMP and ER signaling in greater detail, we used a constitutively active form of ER α , ER α -L536P (21). 293T cells were transfected with 12xGCCG-LUC, an expression vector for ER α -L536P, and/or increasing amounts of an expression vector for BMPR-IA(QD) and/or Smad1 or Smad5, and the LUC activities were measured. As shown in Fig. 2C, BMPR-IA(QD) plus Smad1- or Smad5-induced 12xGCCG-LUC activity was inhibited by ER α -L536P in a dose dependent manner. This inhibition was reversed in the presence of Tamoxifen indicating that it is mediated directly by ER α -L536P (Fig. 2C and data not shown).

In contrast, expression of BMPR-IA(QD) in the presence of either Smad1 or Smad5 resulted in further enhancement of ER α -L536P-induced Vit-LUC activation. These results are consistent with the data presented in Fig. 2A and clearly document the two-way cross-talk between BMP and estrogen receptor signaling in 293T cells.

Physical interactions between ER and Smads in vivo

One of the possible mechanisms that would be consistent with the data described above is that there are direct physical interactions between ERs and Smad1. We tested this possibility by co-immunoprecipitation experiments. 293T cells were transfected with expression vectors encoding ER α -L536P or wild-type ER α together with FLAG-tagged Smad1 and BMPR-IA(QD). Cells that were transfected with ER α were either left untreated or treated with E2, whereas the cells that were transfected with ER α -L536P were left untreated during the course of the experiment. The cells were then lysed and subjected to

immunoprecipitation with an anti-FLAG antibody. Immunoprecipitates were then used in Western analysis with an antiserum against ER α . As shown in Fig. 3A, the constitutively active ER α -L536P and Smad1 were found to be in a complex in 293T cells. Furthermore, consistent with the fact that ER α inhibits BMP-2 signaling only in the presence of E2, ER α -Smad1 interactions were only detected in E2-treated cells (Fig. 3A).

We next tested whether BMP affects ER α -Smad1 interactions. 293T cells were transfected with ER α -L536P together with FLAG-tagged Smad1 in the presence or absence of BMPR-IA(QD) and immunoprecipitation and Western analysis were carried out as above. As shown in Figure 3B, ER α -L536P interacted with Smad1 only in the presence of BMPR-IA(QD), suggesting that stimulation of the BMP signaling pathway is a prerequisite for ER α -Smad1 interactions.

We next determined the domains of ER α that mediate interactions with Smad1, using deletion mutants of ER α -L536P (21). In a previous study, 1 α ,25-dihydroxyvitamin D3 receptor (VDR) was shown to interact with Smad3 through a region in the ligand binding domain (28). We therefore used two deletion mutants of ER α -L536P in which either the DNA binding domain was removed [ER α -L536P(Δ 181-302)] or only the DNA binding domain is present [ER α -L536P(181-302)]. Expression vectors encoding FLAG-tagged Smad1 and/or Myc-tagged ER α -L536P(Δ 181-302) or ER α -L536P(181-302) were transiently transfected into 293T cells, in the presence of BMPR-IA(QD). Cells were lysed, and subjected to immunoprecipitation with an anti-FLAG antibody. Immunoprecipitates were then used in Western blot analysis with an anti-Myc antibody. As shown in Figure 3C, whereas the DNA binding domain alone, ER α -L536P(181-302), interacted with Smad1, ER α -L536P(Δ 181-302) lacking the DNA binding domain was unable to bind Smad1. These

results indicate that in contrast to the VDR-Smad3 interactions (28), efficient ER α -Smad1 interactions require the DNA binding domain of ER α .

To examine the cross-talk between BMP-2 and estrogen signaling pathways under more physiological conditions, we utilized a BMP-2-responsive, ER-positive breast cancer cell line, MCF-7 (24, 25). In parallel with the data in Fig. 1B, co-immunoprecipitation experiments were performed using cell lysates obtained from MCF-7 cells that were either left untreated or were treated with BMP-2 and E2. Similar to the results obtained in transfected 293T cells (Fig. 3A, B), ER α co-immunoprecipitated from MCF-7 cells as a complex with Smad1 and this interaction was dependent on the presence of BMP-2 and E2 (Fig. 3D).

Discussion

Recent studies have identified interactions between TGF- β and steroid receptor signaling pathways. It was reported that Smad3 enhanced VDR transcriptional activity by physically interacting with ligand-induced VDR in complex with SRC-1/TIF2 (28). In prostate cancer cells, AR stimulated TGF- β signaling via direct binding to Smad3 (29), whereas Smad3 repressed AR-mediated transcription (30). However, interaction between GR and Smad3 suppressed TGF- β signaling in hepatoma cells (31). In the case of ER, ER-mediated transcriptional activation was enhanced by TGF- β signaling, whereas ER suppressed Smad3 activity (32).

In contrast, the possible interactions between the BMPs and steroid receptor signaling pathways have not been studied in detail. Recent findings demonstrated that antiestrogens

specifically upregulated BMP4 promoter activity (16) and estrogen opposed the apoptotic effects of BMP7 on tissue remodeling (17). Repression of BMP expression by estrogens may be one of the inhibitory mechanisms that regulate BMP signaling. We here demonstrated an alternative inhibitory pathway, which was due to the direct interaction between components of the two signaling pathways. The findings we present in this paper provide an additional molecular mechanism for at least some of these previous observations. This is also the first time that interactions between BMP-regulated Smads, Smads 1, 5, and 8, with a member of the steroid receptor family has been documented. It would be expected that repression of BMP expression in addition to inhibition of Smad activity may bring a more accentuated repressed state of the BMP pathway than with one mechanism alone. Further work would be required whether these two pathways are active simultaneously in the same cell type.

In the interaction between VDR and Smad3, NH₂-terminal Mad homology 1 (MH1) region of Smad3 and the middle region of the ligand-binding domain (E domain) of VDR were shown to be required for the interaction (28). We had demonstrated that the MH2 domain of Smad3 is required for the cross-talk between ER α and TGF- β signaling in both directions (32). The MH2 domain is known as an important region which interacts with other co-activators such as p300 and CBP (33, 34). ER may compete with p300/CBP in Smad binding as well as Smad co-repressor c-ski (35).

In contrast, in this paper, we found that the middle region of ER containing the DNA binding domain was required for the interaction between ERs and Smads. At present, we do not know if these interactions are direct, or mediated by other cofactors. Future interaction studies performed *in vitro* and more detailed mapping of the domains involved should provide more precise information regarding the detailed molecular mechanisms involved.

Interestingly, the cross-talk between ER and BMPs that we have documented is a mirror image of that observed between AR and TGF- β , but similar to that between VDR and TGF- β . It would be of interest to delineate the mechanism of these similarities and differences since all the steroid receptors involved share significant similarity of structure and function.

Estradiol was previously shown to antagonize TGF- β 1-stimulated type IV collagen synthesis at the level of transcription in murine mesangial cells and this effect may be mediated by interactions with the transcription factor Sp1(36). Other transcriptional cofactors similar to Sp1 may also be involved in the interaction of BMP-regulated Smads with ER. Further work is required to assess this possibility.

We found that TAM concentration that is necessary for reversing the E2 effects is higher in our experiments, consistent with our recent findings on E2-TGF- β signaling cross-talk (32), compared with previously found in similar experiments involving other reporters and signaling pathways (37). We do not know the reason for these difference in the level of TAM that is required for different signaling pathways, but it could be due to changes in the expression level of the factors, or the absence/decreased levels of a specific cofactor that is involved in these activities, in the cell lines under study. Further work is needed to assess these possibilities.

BMPs are also known to induce differentiation of multipotent mesenchymal cells to the osteoblastic (38, 39) and chondroblastic lineages (40) and thus may play a role in bone remodeling and fracture healing. Estrogens have direct effects on osteoblasts (41, 42) and osteoclasts (43) by acting through ER. It has been suggested that many of the estrogen effects on inhibition of osteoclastic activity may be mediated by paracrine action of

bone-active cytokines secreted by osteoblasts, including IL-1 and IL-6 (44, 45), tumor necrosis factor alpha (44), TGF- β (46), and BMP-6 (47). The cross-talk between the BMPs and ERs that we present in this study may be responsible for these important biological outcomes. Further delineation of the interactions between BMP-regulated Smads and ER will not only provide critical information on bone remodeling and kidney biology, but may also be instrumental in the development of new treatment strategies in related diseases.

Figure Legends

Fig. 1. Estrogens inhibit BMP-2-induced gene activation in vivo.

(A) Human renal mesangial cells (HRMC) were either left untreated, or treated with BMP-2(50 ng/ml) and/or E2 (10^{-8} M). COL1A2 expression was monitored by Northern blot analysis of 15 μ g of total RNA for each treatment. The same blot was probed with glyceraldehyde-3-phosphate dehydrogenase (G3PDH) cDNA as control (lower panel).

Relative intensities (Rel. Int.) of the bands shown below the autoradiograms were determined by densitometric analysis. (B) MCF-7 cells were grown in a 6-cm dish and transfected with 12xGCCG-LUC and then stimulated with BMP-2 (50 ng/ml) and/or E2 (10^{-7} M) as indicated. 48 h after transfection, cells were stimulated for an additional 12h. Cells were harvested and relative luciferase activities were measured. The results are presented as fold induction of luciferase activity from triplicate experiments, and the error bars represent the standard deviations. There were no significant changes in basal activity for the different treatments (data not shown).

Fig. 2. Details of the cross-talk between BMP-2 and estrogen receptor signaling in 293T cells.

(A) 293T cells were transfected with 12xGCCG-LUC or Vit-LUC (1 μ g each) together with ER α (1.0 μ g), and/or 1.0 μ g or indicated amounts of BMPR-IA(QD) (0.1 to 1.0 μ g) and Smad5 (0.1 to 0.3 μ g). 48 h after transfection, cells were stimulated for an additional 12h with or without indicated doses (10^{-6} M to 10^{-5} M) of Tamoxifen in the presence or absence of E2 (10^{-8} M or 10^{-7} M), and LUC activities were determined. (B) 293T cells were transfected with 12xGCCG-LUC or Vit-LUC (1 μ g each) together with ER β (1.0 μ g), and/or 1.0 μ g or

indicated amounts of BMPR-IA(QD) (0.1 to 1.0 μg) and Smad5 (0.1 to 0.3 μg). 48 h after transfection, cells were stimulated for an additional 12h with or without indicated doses (10^{-6}M to 10^{-5}M) of Tamoxifen in the presence or absence of E2 (10^{-8}M or 10^{-7}M), and LUC activities were determined. (C) 293T cells were transfected with 12xGCCG-LUC or Vit-LUC (1 μg each) together with ER α -L536P (1.0 μg), and/or 1.0 μg or indicated amounts of BMPR-IA(QD) (0.1 to 1.0 μg) and Smad1 or Smad5 (0.1 to 0.3 μg). 48 h after transfection, cells were stimulated for an additional 12h with or without various doses (10^{-6}M to 10^{-5}M) of Tamoxifen in the presence or absence of E2 (10^{-8}M or 10^{-7}M), and LUC activities were determined. There were no significant changes in basal activity for the different treatments (data not shown).

Fig. 3. Physical interactions between Smad3 and ER.

(A) 293T cells (1×10^7) were transfected with ER α or ER α -L536P (7.5 μg) and FLAG-tagged Smad1 (10 μg) together with BMPR-IA(QD) (3 μg). 48 h after transfection, cells were starved for 12h, followed by treatment with or without E2 (10^{-8}M) for 12h. Cell lysates were then immunoprecipitated with an anti-FLAG antibody, and immunoblotted with an anti-ER α antibody (upper panel) or an anti-FLAG antibody (middle panel). Total cell lysates (20 μg) were blotted with an anti-ER α antibody (lower panel).

(B) Cells (1×10^7) were transfected with ER α -L536P (7.5 μg) and/or FLAG-tagged Smad1 (10 μg) in the presence or absence of HA-tagged BMPR-IA(QD)(3 μg). Cell lysates were then immunoprecipitated with an anti-ER α antibody, and immunoblotted either with anti-FLAG antibody (upper panel) or anti-ER α antibody (middle panel). Total cell lysates

(20 μ g) were blotted with anti-FLAG antibody or anti-HA antibody as indicated (lower panel).

(C) Mapping the Smad1 interaction domain of ER α . 293T cells (1×10^7) were transfected with ER α -L536P (Δ 181–302) or ER α -L536P (181–302) (10 μ g) and FLAG-tagged Smad1 (10 μ g), together with BMPR-IA(QD)(3 μ g). 48 h after transfection, cells were lysed and immunoprecipitated with an anti-ER α antibody, and immunoblotted with anti-Myc antibody (upper panel) or anti-FLAG antibody (middle panel). Total cell lysates (20 μ g) were blotted with anti-Myc antibody (lower panel). The asterisks indicate the migration position of ER α -L536P (Δ 181–302) or ER α -L536P (181–302).

(D) MCF-7 cells (5×10^7 cells) were maintained in DMEM containing 1% FCS for 12 h before stimulation. After 1 h of stimulation with or without BMP-2 (50 ng/ml) and E2 (10^{-8} M), cells were lysed, immunoprecipitated, and immunoblotted with either control IgG, anti-ER α or anti-Smad1 antibody as indicated. Total cell lysates (20 μ g) were blotted with anti-ER α or anti-Smad1 antibody.

Acknowledgements

We thank Dr. M. Kawabata, Dr. K. Miyazono, Dr. P. Chambon, Dr. J. H. White, Dr. J. A. Gustafsson, and Dr. H. Ihn for their kind gifts of reagents.

References

1. Reddi AH 1997 Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. *Cytokine Growth Factor Rev* 8:11-20
2. Hogan BL 1996 Bone morphogenetic proteins: multifunctional regulators of vertebrate development. *Genes Dev* 10:1580-1594
3. Kawabata M, Imamura T, Miyazono K 1998 Signal transduction by bone morphogenetic proteins. *Cytokine Growth Factor Rev* 9:49-61
4. Massagué J 1998 TGF- β signal transduction. *Annu Rev Biochem* 67:753-791.
5. Heldin CH, Miyazono K, ten Dijke P 1997 TGF- β signalling from cell membrane to nucleus through SMAD proteins. *Nature* 390:465-471
6. Derynck R, Zhang Y, Feng XH 1998 Smads: transcriptional activators of TGF- β responses. *Cell* 95:737-740
7. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. *Cell* 83:835-839
8. Kuiper GG, Enmark E, Peltö-Huikko M, Nilsson S, Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary. *Proc Natl Acad Sci USA* 93:5925-5930
9. Mosselman S, Polman J, Dijkema R 1996 ER β : identification and characterization of a novel human estrogen receptor. *FEBS Lett* 392:49-53
10. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JA, Kushner PJ, Scanlan TS 1997 Differential ligand activation of estrogen receptors ER α and ER β at AP1 sites. *Science* 277:1508-1510

11. Couse JF, Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? *Endocr Rev* 20:358-417
12. Sukovich DA, Mukherjee R, Benfield PA 1994 A novel, cell-type-specific mechanism for estrogen receptor-mediated gene activation in the absence of an estrogen-responsive element. *Mol Cell Biol* 14:7134-7143
13. Chen D, Harris MA, Rossini G, Dunstan CR, Dallas SR, Feng JQ, Mundy GR, Harris S E 1997 Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. *Calcif Tissue Int* 60:283-290
14. Palcy S, Goltzman D 1999 Protein kinase signalling pathways involved in the up-regulation of the rat $\alpha 1(I)$ collagen gene by transforming growth factor $\beta 1$ and bone morphogenetic protein 2 in osteoblastic cells. *Biochem J* 343:21-27
15. Xu SC, Harris MA, Rubenstein JL, Mundy GR, Harris SE 2001 Bone morphogenetic protein-2 (BMP-2) signaling to the Col2 $\alpha 1$ gene in chondroblasts requires the homeobox gene Dlx-2. *DNA Cell Biol* 20:359-365
16. van den Wijngaard A, Mulder WR, Dijkema R, Boersma CJ, Mosselman S, van Zoelen EJ, Olijve W 2000 Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells. *Mol Endocrinol* 14:623-633
17. Monroe DG, Jin DF, Sanders MM 1995 Estrogen opposes the apoptotic effects of bone morphogenetic protein 7 on tissue remodeling. *Mol Cell Biol* 20:4626-4634
18. Silbiger S, Neugarten J 1995 The impact of gender on the progression of chronic renal disease. *Am J Kidney Dis* 25:515-533

19. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K 1998 Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. *EMBO J* 17:4056-4065
20. Kusanagi K, Inoue H, Ishidou Y, Mishima HK, Kawabata M, Miyazono K 2000 Characterization of a bone morphogenetic protein-responsive Smad-binding element. *Mol Biol Cell* 11:555-565
21. Eng FC, Lee HS, Ferrara J, Willson TM, White JH 1997 Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics. *Mol Cell Biol* 17:4644-4653
22. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA 1997 Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. *J Clin Endocrinol Metab* 82:4258-4265
23. Ihn H, LeRoy EC, Trojanowska M 1997 Oncostatin M stimulates transcription of the human $\alpha 2$ (I) collagen gene via the Sp1/Sp3-binding site. *J Biol Chem* 272:24666-24672
24. Yamamoto T, Matsuda T, Muraguchi A, Miyazono K, Kawabata K 2001 Cross-talk between IL-6 and TGF- β signaling in hepatoma cells. *FEBS Lett* 492:247-253
25. Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboud SL, Kreisberg J 2000 Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. *Biochim Biophys Acta* 1497:186-196

26. Matsuda T, Yamamoto T, Kishi H, Yoshimura A, Muraguchi A 2000 SOCS-1 can suppress CD3 ζ - and Syk-mediated NF-AT activation in a non-lymphoid cell line. *FEBS Lett* 472:235-240
27. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J 1999 *Dermatol.* Stimulation of type I collagen transcription in human skin fibroblasts by TGF- β : involvement of Smad 3. *J Invest* 112:49-57
28. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K, Kato S 1999 Convergence of transforming growth factor- β and vitamin D signaling pathways on SMAD transcriptional coactivators. *Science* 283:1317-1321
29. Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C 2001 From transforming growth factor- β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. *Proc Natl Acad Sci USA* 98:3018-3023
30. Hayes SA, Zarnegar M, Sharma M, Yang F, Peehl DM, ten Dijke P, Sun Z 2001 SMAD3 represses androgen receptor-mediated transcription. *Cancer Res* 61:2112-2118
31. Song CZ, Tian X, Gelehrter TD 1999 Glucocorticoid receptor inhibits transforming growth factor- β signaling by directly targeting the transcriptional activation function of Smad3. *Proc Natl Acad Sci USA* 96:11776-11781
32. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F. 2001 Cross-talk between transforming growth factor- β and estrogen receptor signaling through Smad3. *J Biol Chem* 276:42908-42914.
33. Janknecht R, Nicholas J, Wells NJ, Hunter T 1998 TGF- β -stimulated cooperation of Smad proteins with the coactivators CBP/p300. *Genes Dev* 12: 2114-2119

34. Nishihara A, Hanai JI, Okamoto N, Yanagisawa J, Kato S, Miyazono K, Kawabata M 1998 Role of p300, a transcriptional coactivator, in signalling of TGF- β Genes Cells 3:613-623.
35. Akiyoshi S, Inoue H, Hanai J, Kusanagi K, Nemoto N, Miyazono K, Kawabata M 1999 c-Ski acts as a transcriptional co-repressor in transforming growth factor- β signaling through interaction with smads. J Biol Chem 274: 35269-35277
36. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, and Gustafsson JA 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β . Endocrinology 138: 863-870
37. Silbiger S, Lei J, Ziyadeh FN, Neugarten J 1998 Estradiol reverses TGF- β 1-stimulated type IV collagen gene transcription in murine mesangial cells. Am J Physiol 274:1113-1118
38. Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V 1992 Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 130:1318-1324
39. Amedee J, Bareille R, Rouais F, Cunningham N, Reddi H, Harmand HF 1994 Osteogenin (bone morphogenic protein 3) inhibits proliferation and stimulates differentiation of osteoprogenitors in human bone marrow. Differentiation 58:157-164
40. Vukicevic S, Luyten FP, Reddi AH 1989 Stimulation of the expression of osteogenic and chondrogenic phenotypes in vitro by osteogenin. Proc Natl Acad Sci USA 86:8793-8797
41. Komm BS, Terpening C M, Benz DJ, Graeme KA, O'Malley BW, Haussler MR 1988 Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241:81-84

42. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL 1988
Evidence of estrogen receptors in normal human osteoblast-like cells. *Science* 241:84-86
43. Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg T 1991 Avian osteoclasts as
estrogen target cells. *Proc Natl Acad Sci USA* 88:6613-6617
44. Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R 1995
Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely
prevent bone loss in the early postovariectomy period. *Endocrinology* 136:3054-3061
45. Manolagas SC, Jilka RL 1995 Bone marrow, cytokines, and bone remodeling. Emerging
insights into the pathophysiology of osteoporosis. *N Engl J Med* 332:305-311
46. Oursler MJ, Cortese C, Keeting PE, Anderson MA, Bonde SK, Riggs BL, Spelsberg TC
1991 Modulation of transforming growth factor- β production in normal human
osteoblast-like cells by 17 β -estradiol and parathyroid hormone. *Endocrinology*
129:3313-3320
47. Rickard DJ, Hofbauer LC, Bonde SK, Gori F, Spelsberg TC, Riggs BL 1998 Bone
morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation
by estrogen. *J Clin Invest* 101:413-422




Fig. 1




Fig. 2




Fig. 3